UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Castration-resistant prostate cancer: latest evidence and therapeutic implications

Therapeutic Advances in Medical Oncology, 2014-07, Vol.6 (4), p.167-179

2014

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non‐Small Cell Lung Cancer With Progression On or After Platinum‐Based Chemotherapy

The oncologist (Dayton, Ohio), 2016-05, Vol.21 (5), p.634-642

2016

Volltextzugriff (PDF)

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

Liver international, 2018-06, Vol.38 (6), p.976-987

2018

Volltextzugriff (PDF)

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer

Cancers, 2015-09, Vol.7 (4), p.1983-1993

2015

Volltextzugriff (PDF)

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease progression in clinical trials

Seminars in oncology, 2017-02, Vol.44 (1), p.3-7

2017

Volltextzugriff (PDF)

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2023-05, Vol.29 (9), p.1651-1657

2023

Volltextzugriff (PDF)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

The oncologist (Dayton, Ohio), 2019-04, Vol.24 (4), p.563-569

2019

Volltextzugriff (PDF)

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis

JNCI : Journal of the National Cancer Institute, 2024-07, Vol.116 (7), p.1043-1050

2024

Volltextzugriff (PDF)

RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?

JNCI : Journal of the National Cancer Institute, 2024-09, Vol.116 (9), p.1534-1534

2024

Volltextzugriff (PDF)

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

The Prostate, 2014-09, Vol.74 (13), p.1278-1285

2014

Volltextzugriff (PDF)

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

Journal of clinical oncology, 2024-05, Vol.42 (14), p.1687-1698

2024

Volltextzugriff (PDF)

FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response

Clinical cancer research, 2023-02, Vol.29 (3), p.685-685

2023

Volltextzugriff (PDF)

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical cancer research, 2024-05, Vol.30 (10), p.2011-2016

2024

Volltextzugriff (PDF)

FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 2024-09, p.OF1-OF6

2024

Volltextzugriff (PDF)

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical cancer research, 2024-09, p.OF1-OF7

2024

Volltextzugriff (PDF)

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma

Clinical cancer research, 2024-08, Vol.30 (15), p.3282-3286

2024

Volltextzugriff (PDF)

An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer

Clinical cancer research, 2020-09, Vol.26 (18), p.4717-4722

2020

Volltextzugriff (PDF)

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2024-05, Vol.42 (15), p.1851-1860

2024

Volltextzugriff (PDF)

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Clinical cancer research, 2022-03, Vol.28 (6), p.1058-1071

2022

Volltextzugriff (PDF)

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies

Clinical cancer research, 2020-12, Vol.26 (24), p.6406-6411

2020

Volltextzugriff (PDF)

Bone-targeting agents in prostate cancer

Cancer and metastasis reviews, 2014-09, Vol.33 (2-3), p.619-628

2014

Volltextzugriff (PDF)

Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Journal of clinical oncology, 2015-04, Vol.33 (10), p.1098-1100

2015

Volltextzugriff (PDF)

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

Cancer discovery, 2023-12, Vol.13 (12), p.2515-2524

2023

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(71)
Berichte
(1)

Sprache

Englisch
(72)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Castration-resistant prostate cancer: latest evidence and therapeutic implications

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non‐Small Cell Lung Cancer With Progression On or After Platinum‐Based Chemotherapy

Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents

Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1–defined disease progression in clinical trials

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis

RE: Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma

An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer

US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies

Bone-targeting agents in prostate cancer

Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

Suchergebnisse filtern